Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations

Background: Although superior clinical benefits of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer (NSCLC) had been reported with different sensitivity, the sensitivity of second-line TKIs in NSCLC patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer
Main Authors: Zheng, Zhen, Jin, Xiance, Lin, Baochai, Su, Huafang, Chen, Hanbin, Fei, Shaoran, Zhao, Lihao, Deng, Xia, Xie, Deyao, Xie, Congying
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5370503/
https://ncbi.nlm.nih.gov/pubmed/28367239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.16959
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados